Cell type-associated traits map for the [Lake_2017_VisualCortex_Excitatory neuron 8][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [Lake_2017_VisualCortex_Excitatory neuron 8]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 6.96e-4 |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 1.00e-2 | 1.55e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 1.00e-3 | 1.80e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 1.00e-5 | 4.79e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 5.00e-2 | 1.45e-4 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 5.00e-2 | 1.61e-2 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 1.00e-2 | 3.77e-3 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 1.00e-3 | 3.46e-2 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 4.45e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 5.00e-2 | 6.61e-4 |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 5.00e-2 | 1.56e-2 |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-2 | 3.92e-2 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-4 | 2.50e-2 |
BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 5.00e-2 | 2.98e-3 |
BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 1.00e-3 | 2.03e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 9.15e-4 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 2.07e-2 |
Breast Cancer | Breast Cancer | MTC | Hunter | 2007 | NA | 1145 | 5.00e-2 | 2.46e-2 |
Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 3.68e-2 |
Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 1.00e-2 | 9.34e-3 |
Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 5.00e-2 | 2.18e-2 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 2.08e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 5.83e-3 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 6.98e-5 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.81e-3 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 6.98e-5 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 1.81e-3 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 5.00e-2 | 3.53e-3 |
Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 5.00e-2 | 1.54e-4 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 4.66e-3 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 5.00e-2 | 4.92e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-2 | 3.40e-2 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 5.00e-2 | 2.93e-2 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 5.00e-2 | 1.02e-2 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-2 | 9.11e-4 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-3 | 2.43e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 5.00e-2 | 6.86e-3 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-2 | 4.23e-2 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 8.45e-3 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 3.28e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 2.33e-7 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-3 | 9.00e-4 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-4 | 3.71e-3 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-5 | 7.39e-3 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 5.00e-2 | 6.52e-6 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-2 | 6.10e-4 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 5.00e-2 | 1.29e-2 |
Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 5.00e-2 | 2.41e-2 |
Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 1.00e-2 | 7.16e-4 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 5.00e-2 | 2.61e-2 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-2 | 6.35e-3 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 5.00e-2 | 1.99e-3 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-2 | 1.33e-3 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-3 | 2.75e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 5.00e-2 | 8.24e-3 |
Visual Refractive Error | Visual Refractive Error | MTC | Stambolian | 2013 | NA | 7280 | 5.00e-2 | 2.72e-2 |
Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 5.00e-2 | 1.45e-2 |
Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 5.00e-2 | 1.92e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Boger | 2011 | NA | 31580 | 1.00e-2 | 7.35e-4 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 1.55e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 1.60e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 4.40e-2 |
Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 5.00e-2 | 4.53e-4 |
Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-2 | 3.39e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 7.64e-3 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 1.00e-2 | 2.60e-2 |
Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 2.32e-4 |
Alcohol Consumption | Alcohol Consumption Men Dichotomous | MTC | Schumann | 2016 | NA | 26991 | 5.00e-2 | 2.09e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 1.17e-3 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-2 | 3.40e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 6.15e-4 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-2 | 8.44e-3 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 6.30e-3 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 2.52e-2 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-3 | 3.76e-2 |
Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 5.00e-2 | 7.70e-3 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 5.00e-2 | 1.39e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 5.00e-2 | 1.95e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 4.44e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 1.27e-3 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 2.00e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-4 | 2.21e-2 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 1.36e-2 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 3.43e-3 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-3 | 3.34e-3 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-4 | 2.21e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 1.78e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 3.85e-2 |
Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 2.29e-2 |
Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 1.00e-2 | 2.15e-2 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 5.00e-2 | 3.42e-2 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 1.00e-2 | 2.34e-2 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 1.00e-3 | 2.97e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 5.00e-2 | 2.29e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-2 | 2.36e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-3 | 7.21e-3 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 1.88e-5 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 1.80e-2 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.37e-2 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.26e-2 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.65e-2 |
Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.43e-2 |
Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 8.71e-3 |
Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.99e-2 |
Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.06e-4 |
Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 5.12e-3 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.14e-2 |
BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 5.00e-2 | 8.60e-3 |
BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 1.00e-2 | 1.77e-3 |
BMI Age Stratified | BMI Women Age Under 50 | MTC | Winkler | 2015 | NA | 60654 | 5.00e-2 | 1.12e-2 |
BMI | BMI European Women | MTC | Locke | 2015 | NA | 132115 | 5.00e-2 | 2.12e-2 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.97e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.10e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.12e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.23e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.47e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.29e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.53e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.60e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 2.18e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 1.41e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.16e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 9.95e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.66e-4 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.89e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 1.84e-4 |
BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 1.66e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 8.92e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.22e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.40e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 7.80e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 7.90e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.40e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 3.04e-6 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-2 | 1.42e-3 |
Cognitive Functions | Memory | MTC | Davies | 2016 | NA | 112067 | 5.00e-2 | 5.22e-3 |
Cognitive Functions | Reaction Time | MTC | Davies | 2016 | NA | 111483 | 1.00e-5 | 4.44e-2 |
Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 5.00e-2 | 7.71e-5 |
Diarrhoeal Disease | Diarrhea Age 1 | MTC | Bustamante | 2016 | 2693 | 3065 | 5.00e-2 | 2.10e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 5.00e-2 | 2.18e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 1.00e-3 | 2.58e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 2 | MTC | Bustamante | 2016 | 990 | 5243 | 5.00e-2 | 3.86e-3 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-2 | 1.49e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 3.12e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 3684 | 5.00e-2 | 4.92e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 5.72e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 3.64e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 5.75e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 1.20e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 5.00e-2 | 2.42e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 1.00e-2 | 5.01e-4 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 1.82e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 2.25e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 3.37e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 4.24e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-2 | 2.14e-6 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-3 | 3.16e-6 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-4 | 8.83e-5 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-5 | 3.13e-4 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 4.62e-5 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 1.56e-3 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-3 | 9.70e-4 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-4 | 8.69e-4 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-5 | 1.33e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 1.09e-5 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 1.10e-3 |
Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.69e-2 |
Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.31e-2 |
Facial Shape | Mod11 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.02e-2 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.30e-2 |
Facial Shape | Mod16 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.81e-3 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.12e-2 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.23e-2 |
Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.35e-2 |
Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.38e-2 |
Facial Shape | Mod27 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.76e-2 |
Facial Shape | Mod27 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.28e-2 |
Facial Shape | Mod29 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.50e-2 |
Facial Shape | Mod29 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.58e-2 |
Facial Shape | Mod31 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.56e-2 |
Facial Shape | Mod32 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.36e-2 |
Facial Shape | Mod33 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.76e-4 |
Facial Shape | Mod33 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.54e-2 |
Facial Shape | Mod35 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.37e-4 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.46e-4 |
Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 8.32e-5 |
Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 5.31e-3 |
Facial Shape | Mod38 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.32e-3 |
Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.01e-4 |
Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 9.65e-3 |
Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.23e-2 |
Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.38e-2 |
Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.60e-2 |
Facial Shape | Mod5 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.10e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.20e-2 |
Facial Shape | Mod62 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.35e-2 |
Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.85e-4 |
Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 8.44e-3 |
Forced Expiratory Volume | Forced Expiratory Volume | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 3.49e-2 |
Forced Expiratory Volume | Forced Expiratory Volume | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-2 | 3.72e-2 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 4.51e-2 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-2 | 4.88e-2 |
Gestational Weight Gain | Late Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 8641 | 5.00e-2 | 2.55e-2 |
Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.24e-2 |
Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.26e-2 |
Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.48e-2 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 1.00e-2 | 2.00e-3 |
Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 1.00e-3 | 8.59e-4 |
Glycemic Traits BMI Corrected | Fasting Insulin | MTC | Manning | 2012 | NA | 51750 | 1.00e-3 | 2.97e-2 |
Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 3.28e-2 |
Insulin Secretion | Acute Insulin Response | MTC | Wood | 2017 | NA | 2087 | 1.00e-2 | 4.22e-2 |
Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 8.14e-3 |
Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.60e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.57e-3 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 3.48e-2 |
Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 5.00e-2 | 1.65e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 2.58e-2 |
Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 5.00e-2 | 7.03e-4 |
Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-2 | 3.62e-2 |
Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-3 | 1.59e-2 |
Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 1.00e-3 | 2.62e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 4.39e-3 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 3.40e-3 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 7.35e-3 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-3 | 4.09e-2 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 2.63e-3 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 2.41e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-3 | 9.98e-3 |
New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 3.26e-2 |
Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.40e-2 |
Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 8.15e-3 |
Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 3.76e-2 |
Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.30e-3 |
Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 3.40e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 2.74e-3 |
Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 2.14e-3 |
Reproductive Behavior | Age First Birth Female | MTC | Barban | 2016 | NA | 189656 | 5.00e-2 | 1.67e-2 |
Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 5.00e-2 | 3.71e-3 |
Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 5.00e-2 | 6.61e-4 |
Reproductive Behavior | Number Children Ever Born Male | MTC | Barban | 2016 | NA | 103909 | 5.00e-2 | 7.54e-3 |
Reproductive Behavior | Number Children Ever Born Male | MTC | Barban | 2016 | NA | 103909 | 1.00e-2 | 2.64e-2 |
Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 5.00e-2 | 1.96e-2 |
Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 1.00e-2 | 9.70e-3 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 2.81e-3 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 5.00e-2 | 6.94e-4 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-2 | 2.22e-2 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 5.00e-2 | 2.01e-3 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 1.00e-2 | 1.62e-2 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 1.00e-3 | 2.97e-2 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 1.00e-4 | 2.87e-2 |
Stroke (ischemic) | All Ischemic Stroke | MTC | Traylor | 2017 | 12389 | 62004 | 5.00e-2 | 7.75e-3 |
Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 1.00e-2 | 2.45e-2 |
Smoking | Cigarettes Per Day | ETC | Furberg | 2010 | NA | 38181 | 5.00e-2 | 5.35e-3 |
Smoking | Current Vs Former Discrete | MTC | Furberg | 2010 | 20619 | 15226 | 5.00e-2 | 2.78e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 1.19e-5 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-3 | 1.44e-2 |
Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 2.82e-2 |
Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 2.27e-2 |
Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.05e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 5.00e-2 | 9.42e-3 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 8.06e-3 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-2 | 3.79e-3 |
Waist Format 1 | Hip Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.03e-2 |
Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 1.44e-2 |
Waist Format 1 | Waist Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 4.01e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 2.59e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 3.17e-2 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 5.00e-2 | 1.64e-4 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-2 | 9.87e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-2 | 3.33e-5 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-3 | 4.63e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 2.07e-2 |
PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 5.74e-3 |
COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 5.00e-2 | 1.44e-2 |
COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-3 | 2.02e-2 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 3.70e-2 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 5.00e-2 | 2.16e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 2.59e-4 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-4 | 2.14e-3 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 5.00e-2 | 4.94e-4 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-2 | 4.49e-4 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 3.44e-4 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-2 | 4.92e-2 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-3 | 1.29e-2 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 5.00e-2 | 7.06e-4 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 1.00e-3 | 1.44e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 3.29e-3 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 2.48e-3 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-2 | 2.96e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-4 | 3.11e-2 |
Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 5.00e-2 | 7.30e-4 |
Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 1.00e-2 | 1.47e-2 |
Sleep | Diurnal inactivity | ETC | Jones | 2019 | NA | 84757 | 5.00e-2 | 1.30e-8 |
Sleep | Diurnal inactivity | ETC | Jones | 2019 | NA | 84757 | 1.00e-2 | 1.64e-5 |
Sleep | Diurnal inactivity | ETC | Jones | 2019 | NA | 84757 | 1.00e-3 | 1.87e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 5.39e-4 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.29e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 2.49e-2 |
Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 4.36e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 4.48e-4 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 5.87e-4 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-4 | 2.17e-2 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 2.30e-7 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 8.27e-5 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 6.13e-3 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 2.30e-7 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 8.27e-5 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 6.13e-3 |
Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 5.00e-2 | 4.58e-2 |
K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 5.00e-2 | 5.18e-3 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 5.00e-2 | 1.17e-8 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-2 | 7.92e-7 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-3 | 5.68e-3 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-4 | 2.50e-2 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-5 | 2.48e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 5.00e-2 | 1.93e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-3 | 3.17e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-4 | 3.85e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-5 | 5.10e-3 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-2 | 2.25e-9 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-3 | 2.69e-7 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-4 | 4.06e-6 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-5 | 1.08e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 2.78e-2 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-2 | 8.93e-6 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-3 | 6.20e-4 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-4 | 1.82e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-3 | 8.20e-5 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-4 | 8.88e-5 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-5 | 8.53e-5 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-2 | 5.81e-6 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-3 | 5.31e-7 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-4 | 1.04e-3 |
Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-5 | 1.22e-3 |
Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 5.00e-2 | 1.52e-2 |
Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 1.00e-2 | 2.53e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 1.79e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 9.52e-3 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 6.99e-3 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 8.99e-5 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 7.23e-7 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 2.61e-4 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 2.85e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-2 | 6.45e-5 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 1.05e-5 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 2.21e-4 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-5 | 1.22e-3 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 5.00e-2 | 8.00e-3 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-3 | 4.51e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 5.00e-2 | 1.03e-3 |
Smoking | Smoking behaviour, cigarettes smoked per day | ETC | Liua | 2019 | NA | 377334 | 5.00e-2 | 9.39e-5 |
Smoking | Smoking behaviour, cigarettes smoked per day | ETC | Liua | 2019 | NA | 377334 | 1.00e-2 | 2.90e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 5.00e-2 | 3.25e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 1.00e-2 | 2.51e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 1.00e-3 | 8.90e-3 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 5.00e-2 | 4.56e-5 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-2 | 4.50e-3 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 5.00e-2 | 6.59e-6 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-2 | 1.05e-3 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-3 | 3.13e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-4 | 7.04e-3 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-5 | 1.56e-2 |
Positive affect | Positive affect | ETC | Baselmans | 2019 | NA | 410603 | 5.00e-2 | 3.43e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-2 | 1.15e-9 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-3 | 3.73e-6 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-4 | 7.47e-5 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-5 | 4.12e-3 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 3.54e-3 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 6.40e-3 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 9.82e-5 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.06e-5 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 9.63e-3 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.39e-6 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 9.53e-4 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 8.85e-4 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 1.85e-3 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-5 | 2.43e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.82e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.46e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 1.04e-2 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.11e-4 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 3.42e-2 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 5.00e-2 | 3.62e-3 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-2 | 2.56e-2 |
Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.63e-2 |
Hippocampal volume | Hippocampal fissure volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.47e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.59e-2 |
Fimbria volume | Fimbria volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.45e-2 |
Hippocampal volume | Hippocampal fissure volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.73e-2 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.11e-3 |
Hippocampal volume | Hippocampal subfield CA4 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.23e-3 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.21e-2 |
Subiculum volume | Subiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.43e-2 |
Parasubiculum volume | Presubiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.21e-2 |
Parasubiculum volume | Presubiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.84e-2 |
ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 5.00e-2 | 6.65e-3 |
Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 5.00e-2 | 3.02e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 1.84e-2 |
AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 5.00e-2 | 1.88e-4 |
AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 1.00e-2 | 3.60e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 8.44e-6 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-2 | 3.24e-5 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 2.83e-2 |
Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 5.00e-2 | 8.72e-3 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 5.00e-2 | 3.30e-2 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 1.00e-2 | 2.71e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-2 | 4.46e-2 |
Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 5.00e-2 | 1.07e-2 |
Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 5.00e-2 | 1.87e-4 |
Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 8.15e-3 |
Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-2 | 3.96e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 5.00e-2 | 4.34e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 1.62e-2 |
Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 5.00e-2 | 3.40e-4 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.81e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.71e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT5) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.41e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 3.36e-2 |
Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 1.54e-2 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 5.00e-2 | 5.77e-3 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 1.00e-2 | 1.68e-3 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 7,834 | 15,258 | 5.00e-2 | 4.16e-2 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-2 | 1.14e-6 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-3 | 7.76e-5 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-4 | 8.23e-3 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 4.46e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-2 | 1.02e-3 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-3 | 1.46e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 8.25e-4 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-2 | 4.46e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 5.00e-2 | 1.02e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 3.70e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 1.99e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 2.44e-3 |
Parietal lobe volume | Parietal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.48e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-2 | 3.64e-5 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-3 | 5.03e-4 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-4 | 1.96e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-5 | 7.22e-4 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-2 | 3.11e-8 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-3 | 4.19e-6 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-4 | 6.26e-5 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-5 | 5.73e-3 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-3 | 1.46e-8 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-4 | 3.14e-8 |
Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-5 | 5.55e-5 |
Birth | Post-term birth | ETC | Liu X | 2019 | 7,888 | 60,148 | 1.00e-3 | 3.23e-2 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 5.00e-2 | 1.66e-2 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-2 | 4.16e-2 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-2 | 7.21e-4 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-3 | 5.08e-3 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-4 | 9.42e-3 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-5 | 1.66e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 5.85e-5 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-5 | 1.60e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-2 | 1.34e-4 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-3 | 6.30e-4 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-4 | 7.44e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-5 | 4.12e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-3 | 1.55e-4 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-4 | 1.86e-4 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-5 | 4.01e-3 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 5.00e-2 | 2.05e-2 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 1.04e-2 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-4 | 2.86e-6 |
BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 434,794 | 1.00e-5 | 5.13e-7 |
Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 5.00e-2 | 3.71e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 5.00e-2 | 2.40e-3 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-2 | 2.87e-2 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 5.00e-2 | 2.32e-3 |
Waist to hip ratio | Waist-hip ratio variance | ETC | Wang H | 2019 | NA | 347,134 | 5.00e-2 | 2.31e-2 |
Waist to hip ratio | Waist-hip ratio variance | ETC | Wang H | 2019 | NA | 347,134 | 1.00e-2 | 4.52e-2 |
Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 5.00e-2 | 1.39e-3 |
Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-2 | 3.52e-2 |
Birth weight | Birth weight variance | ETC | Wang H | 2019 | NA | 197,758 | 5.00e-2 | 8.47e-3 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 1.94e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 4.52e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 5.00e-2 | 2.65e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 5.00e-2 | 4.95e-2 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 1.20e-3 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-2 | 4.45e-2 |
BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 5.00e-2 | 1.65e-3 |
BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-2 | 1.59e-2 |
PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 1.00e-3 | 1.88e-2 |
PD | Parkinson's disease in GBA mutation carriers (age at onset) | ETC | Blauwendraat C | 2020 | NA | 1,353 | 5.00e-2 | 3.08e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 1.00e-2 | 2.60e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 1.70e-2 |
Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 5.00e-2 | 7.16e-3 |
Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 1.00e-2 | 8.62e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 5.42e-4 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 2.47e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 3.82e-4 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 1.05e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 4.41e-3 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-2 | 3.97e-3 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-2 | 3.31e-7 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-3 | 5.51e-3 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-4 | 8.75e-3 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-5 | 7.63e-4 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.01e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.99e-3 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.09e-3 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.39e-6 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.20e-2 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.94e-2 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.15e-2 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-2 | 1.69e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 3.76e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 2.52e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 4.84e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-2 | 5.01e-5 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-3 | 9.34e-5 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-4 | 2.32e-4 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-5 | 3.02e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 5.00e-2 | 1.01e-6 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-2 | 5.67e-5 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 8.56e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-4 | 8.35e-4 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-5 | 5.40e-3 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 5.00e-2 | 2.06e-7 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-2 | 1.35e-4 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-3 | 8.86e-5 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-4 | 2.47e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 5.00e-2 | 1.84e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-2 | 4.56e-2 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 5.00e-2 | 1.19e-4 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-2 | 2.29e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 2.09e-3 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 1.00e-3 | 3.58e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 5.00e-2 | 2.43e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.